Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on SENS-401 to Prevent Hearing Loss Caused by Cisplatin in Adults with Cancer

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as cisplatin-induced hearing loss, which can occur in patients undergoing treatment for cancer. The study is investigating a new treatment called SENS-401, also known as Arazasetron besylate, which is taken as a film-coated tablet. The purpose of the study is to evaluate whether SENS-401 can help prevent hearing loss caused by the cancer medication cisplatin.

Participants in the study will be adults who are receiving cisplatin as part of their cancer treatment. The study will involve taking SENS-401 at a dose of 43.5 mg twice a day for up to 23 weeks. The effectiveness of SENS-401 in preventing hearing loss will be assessed four weeks after the last dose of cisplatin. Some participants will receive a placebo instead of SENS-401 to compare the outcomes.

The study will monitor changes in hearing ability by measuring hearing thresholds, which are the quietest sounds a person can hear, at various frequencies. This will help determine if SENS-401 is effective in protecting against hearing loss. The trial is expected to continue until March 2025, with participants being recruited since December 2022.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria such as age, ability to provide consent, and medical condition.

    Participants must be adults with a neoplastic disease scheduled to receive chemotherapy including cisplatin.

  2. Step 2

    Medication administration

    The study involves the administration of SENS-401 at a dose of 43.5 mg taken twice daily (b.i.d., which means 'bis in die' or twice a day).

    This medication is taken for up to 23 weeks to help prevent hearing loss caused by cisplatin.

  3. Step 3

    Treatment with cisplatin

    Participants receive chemotherapy that includes cisplatin, with a minimum dose of 70 mg/m² per cycle and a total dose of at least 210 mg/m².

    The goal is to evaluate the effectiveness of SENS-401 in preventing hearing loss from this treatment.

  4. Step 4

    Hearing assessment

    Hearing is assessed using an audiogram that measures hearing thresholds at frequencies between 0.5 and 12.5 kHz.

    This assessment occurs 4 weeks after the last cisplatin treatment to determine any changes in hearing ability.

  5. Step 5

    Completion of study

    The study is expected to conclude by March 31, 2025.

    Participants' hearing data will be analyzed to evaluate the primary endpoint, which is the change in hearing threshold from the baseline.

Who can join the trial?

7 criteria

  • You must be **18 years or older** at the time of signing the consent form.
  • You need to be able to give signed informed consent, which means you understand and agree to the study's requirements and restrictions.
  • If you are a **female**, you must not be pregnant or breastfeeding. You must either not be able to have children or agree to use birth control for at least 30 days after the last dose of the study drug if you do not receive cisplatin, or for 6 months after the last dose of cisplatin.
  • If you are a **male**, you must agree to use birth control and not donate sperm for at least 30 days after the last dose of the study drug if you do not receive cisplatin, or for 6 months after the last dose of cisplatin.
  • You must have a **neoplastic disease**, which means you have a type of cancer, and you are planned to be treated with a chemotherapy that includes a dose of cisplatin of at least 70 mg/m² per cycle and a total dose of at least 210 mg/m².
  • Your hearing test results must meet specific criteria: a hearing threshold of 30 decibels (dB) or less at 500 Hz, 40 dB or less at 1-2 kHz, 60 dB or less at 4-6 kHz, and 80 dB or less at 8 kHz, in either both ears or one ear for a maximum of 30% of the subjects in each study group.
  • The study doctor must believe you have a **life expectancy** of at least 6 months.

Who cannot join the trial?

3 criteria

  • Patients who have not experienced hearing loss caused by the medication cisplatin cannot participate. Cisplatin is a drug used to treat cancer, and it can sometimes cause hearing problems.
  • Patients who are not within the specified age range for the study cannot participate. The study is open to certain age groups only.
  • Patients who are part of a vulnerable population cannot participate. A vulnerable population includes groups of people who might need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • SENS-401

    is a medication being studied to see if it can help prevent hearing damage caused by another drug called cisplatin. It is given to patients who have cancer and are receiving cisplatin as part of their treatment. The study is looking at how well SENS-401 works when taken for up to 23 weeks.

  • Cisplatin

    is a chemotherapy drug used to treat various types of cancer. While it can be effective in fighting cancer, it can also cause side effects, including damage to the ears, which can lead to hearing loss. This study is testing whether SENS-401 can help protect against this side effect.

What is already known about the treatment

SENS-401 – SENS-401 is administered orally in the form of tablets, taken twice daily. It is currently being studied in clinical trials to assess its effectiveness in preventing hearing loss caused by the chemotherapy drug cisplatin in patients with cancer. The main therapeutic indication for SENS-401 is to protect against ototoxicity, which is a type of hearing damage. At the molecular level, SENS-401 works by protecting the inner ear cells from damage caused by toxic substances. It is classified pharmacologically as an otoprotective agent.

Investigated diseases

Cisplatin-Induced Hearing Loss – This condition occurs as a side effect of the chemotherapy drug cisplatin, which is used to treat various types of cancer. The drug can damage the inner ear, leading to hearing loss that may affect one or both ears. The hearing loss can range from mild to severe and often involves high-frequency sounds. It typically develops during or shortly after the course of cisplatin treatment. The progression of hearing loss can vary, with some individuals experiencing gradual worsening over time. The condition is more common in patients receiving higher doses or prolonged treatment with cisplatin.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-511713-38-00Protocol codeSENS-401-202Estimated enrolment60 patientsSponsorSensorion

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).